← All trials
NCT04676243
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Dec 19, 2020
- Last posted
- Apr 27, 2021
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of HeidelbergLead sponsor
- University of HeidelbergReponsible party - principal investigator
- Daiichi SankyoCollaborator
- University of HeidelbergOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.